Afuresertib is primarily used in the field of oncology as a potent and selective inhibitor of AKT (protein kinase B). It is being investigated for its potential to treat various types of cancers, including breast, ovarian, and gastric cancers, where the AKT pathway is often dysregulated. By targeting this pathway, Afuresertib aims to inhibit tumor growth and enhance the efficacy of other cancer therapies. Clinical trials are ongoing to evaluate its safety, tolerability, and effectiveness in combination with other treatments, offering hope for improved outcomes in patients with advanced or resistant cancers.